Policy

GLP-1 Prescribing Policy

Safe, effective and lawful prescribing, supply and monitoring of GLP-1 and GLP-1/GIP receptor agonist medicines for weight management

For Weight Loss ClinicRef BS-WEI-POL-001See a sample (PDF) →
£54.99
One-off purchase · no VAT · instant download
  • Instant download after checkout
  • Editable Microsoft Word (.docx)
  • Mapped to the CQC standards
  • Optional 3-monthly updates

What's inside

This policy is fully drafted and structured, ready to brand and complete for your service. It covers:

  • 1. Purpose
  • 2. Scope
  • 3. Policy statement
  • 4. Definitions
  • 5. Regulatory and clinical framework
  • 6. Eligibility and clinical assessment criteria
  • 7. Pregnancy, contraception and pre-surgical safeguards
  • 8. Independent verification, prescribing and supply procedure
  • 9. Titration, ongoing review and monitoring
  • 10. Safeguarding, mental health and vulnerable patients
  • 11. Adverse events, pharmacovigilance and recalls
  • 12. Roles and responsibilities
  • 13. Training and competence
  • 14. Records, monitoring and audit
  • 15. Related documents
  • 16. Appendix A - Pre-prescribing safety checklist
  • 17. Appendix B - Repeat-supply review form
  • 18. Version control and review
  • 19. Disclaimer

Legislation & standards it maps to

  • Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 (in particular Regulation 9 (Person-centred care), Regulation 11 (Need for consent), Regulation 12 (Safe care and treatment), Regulation 17 (Good governance), Regulation 18 (Staffing), Regulation 19 (Fit and proper persons employed) and Regulation 20 (Duty of candour))
  • Care Quality Commission (Registration) Regulations 2009
  • Human Medicines Regulations 2012 (as amended)
  • Medicines and Healthcare products Regulatory Agency (MHRA) safety guidance on glucagon-like peptide-1 (GLP-1) receptor agonist medicines and the prescription-only medicine advertising Enforcement Notice (September 2025)
  • General Pharmaceutical Council (GPhC) Standards for Pharmacy Professionals and Guidance for Registered Pharmacies Providing Pharmacy Services at a Distance (2022, updated 2025)
  • General Medical Council (GMC) Good Medical Practice (2024) and Good Practice in Prescribing and Managing Medicines and Devices
  • National Institute for Health and Care Excellence (NICE) Technology Appraisal TA1026 (tirzepatide) and Technology Appraisal TA875 (semaglutide) for weight management
  • Data Protection Act 2018 and the UK General Data Protection Regulation (UK GDPR)

Who it applies to

All prescribers (independent prescribers and medical practitioners), responsible pharmacists, pharmacy professionals, clinical and non-clinical staff, locums, agency workers and contractors involved in the assessment, prescribing, dispensing, supply or monitoring of weight management medicines at [Organisation Name]

Glossary

Plain-English explanations of the technical terms and legislation used in this document.

Adverse drug reaction
An unwanted or harmful response to a medicine taken at a normal dose.
Adverse event
Any unexpected or unwanted occurrence linked to a treatment that harms, or could harm, a patient.
Advertising Standards Authority (ASA)
The UK body that regulates advertising and can act against misleading or unlawful adverts.
Anaesthesia
The use of medicines to remove sensation or induce sleep so a procedure or operation can be carried out.
Aspiration risk
The risk that stomach contents pass into the lungs, which is more likely around surgery if the stomach empties slowly.
Body mass index (BMI)
A measure of body weight relative to height, used to judge whether a person is underweight, a healthy weight or overweight.
Care Quality Commission (CQC)
The independent regulator of health and social care services in England.
Cold chain
Keeping vaccines and certain medicines within a safe temperature range from delivery to use.
Comorbidity
An additional health condition a person has alongside the main condition being treated.
Contraindication
A reason why a particular medicine or treatment should not be given because it could cause harm.
Data Protection Act 2018
The UK law that sits alongside the UK GDPR and governs how personal information must be handled.
Data Protection Officer (DPO)
The person responsible for overseeing how an organisation protects personal data and follows data-protection law.
Diabetic ketoacidosis
A serious, potentially life-threatening complication of diabetes caused by a severe lack of insulin.
Dyslipidaemia
An abnormal level of fats such as cholesterol in the blood, which can raise the risk of heart disease.
Excipients
The inactive ingredients in a medicine, such as fillers or preservatives, alongside the active drug.
Formulary
An approved list of medicines that a service has agreed may be prescribed and supplied.
Fundamental standards
The minimum standards of safety and quality below which care must never fall.
Gastroparesis
A condition in which the stomach empties more slowly than normal.
General Medical Council (GMC)
The body that registers and regulates doctors in the UK and sets the standards they must meet.
General Pharmaceutical Council (GPhC)
The body that registers and regulates pharmacists, pharmacy technicians and registered pharmacies in Great Britain.
General practitioner (GP)
A doctor based in the community who provides general medical care and coordinates a patient's overall health.
GIP (glucose-dependent insulinotropic polypeptide)
A natural gut hormone involved in regulating blood sugar and appetite; some weight-management medicines act on its receptor.
GLP-1 (glucagon-like peptide-1)
A natural gut hormone that reduces appetite and slows stomach emptying; medicines that copy its action are used for weight management.
GLP-1 receptor agonist
A medicine that mimics the GLP-1 hormone to reduce appetite and food intake.
Hypersensitivity
An exaggerated immune response to a substance, ranging from a mild allergy to a severe reaction.
Hypertension
Persistently raised blood pressure, which increases the risk of heart disease and stroke.
Incretin
A type of gut hormone, such as GLP-1 and GIP, that helps control blood sugar and appetite after eating.
Independent prescriber
A trained healthcare professional, such as a pharmacist or nurse, who is qualified to prescribe medicines in their own right within their competence.
Information governance
The framework for handling people's personal and health information legally, securely and appropriately.
International non-proprietary name
The official generic name of a medicine's active ingredient, as opposed to a manufacturer's brand name.
Marketing authorisation
The official licence that allows a medicine to be sold and used for specified purposes in the UK.
Medicines and Healthcare products Regulatory Agency (MHRA)
The UK body that regulates medicines and medical devices and monitors their safety.
Medullary thyroid carcinoma
A rare type of thyroid cancer; a personal or family history of it makes some weight-management medicines unsuitable.
Multiple Endocrine Neoplasia syndrome type 2
An inherited condition that increases the risk of certain tumours, including thyroid cancer.
National Institute for Health and Care Excellence (NICE)
The body that produces evidence-based guidance and recommendations on treatments and care in England.
Nominated Individual
The senior person responsible to the regulator for supervising how a service is provided.
Obstructive sleep apnoea
A condition where breathing repeatedly stops and starts during sleep because the airway becomes blocked.
Off-label
Using a licensed medicine in a way not covered by its official licence, such as for a different condition or dose.
Pancreatitis
Inflammation of the pancreas, which can cause severe abdominal pain and be serious.
Perioperative
The period around an operation, including before, during and shortly after surgery.
Pharmacovigilance
The ongoing monitoring of the safety of medicines once they are in use, to detect and act on side effects.
Prediabetes
Blood sugar levels that are higher than normal but not yet high enough to be diagnosed as diabetes.
Prescription-only medicine (POM)
A medicine that may lawfully be supplied only on the instruction of an appropriate prescriber.
Registered Manager
The person registered with the regulator as responsible for the day-to-day running of a service.
Regulated activity
A type of care or treatment the law requires a provider to register with the regulator to deliver.
Responsible Pharmacist
The pharmacist legally in charge of the safe and effective running of a pharmacy at a given time.
Safeguarding
Protecting people's health, wellbeing and rights and keeping them safe from abuse, harm or neglect.
Safety-netting
Giving a patient clear advice on warning signs to watch for and exactly when and how to seek further help.
Single assessment framework
The structure the regulator uses to judge a service, built around quality statements and five key questions (safe, effective, caring, responsive, well-led).
Summary of Product Characteristics (SmPC)
The official document describing how a medicine should be used, including doses, warnings and side effects.
Titration
Gradually adjusting a medicine's dose, usually increasing it in steps, to reach the right level safely.
Type 1 diabetes
A condition where the body produces little or no insulin and requires lifelong insulin treatment.
Type 2 diabetes
A common condition where the body does not use insulin properly, leading to raised blood sugar.
UK General Data Protection Regulation (UK GDPR)
The UK's main data-protection law governing how personal information is collected and used.
Yellow Card Scheme
The UK system for reporting suspected side effects of medicines and faulty medical products to the MHRA.

How it works

  1. Buy securely with Stripe - instant, no VAT, no account needed.
  2. Download your editable Word file from the link we email you straight away.
  3. Complete the placeholders for your service, then have it approved before use.
  4. Add the optional updates subscription and we keep it current as guidance changes.

Related documents

PolicyCardiovascular Assessment Policy£54.99
PolicyPsychological Screening Policy£54.99
PolicyInformed Consent Policy£54.99
PolicyEating Disorder Safeguarding Policy£54.99

Need the whole set?

Buy the full Weight Loss Clinic pack and save versus buying documents individually.

View the Weight Loss Clinic pack